Department of Biomedical Sciences, Microarray Core Facility, Cornell University, Ithaca, NY 14853, USA.
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14240-5. doi: 10.1073/pnas.1017536108. Epub 2011 Aug 9.
Recent observations suggest that p53 mutations are responsible not only for growth of primary tumors but also for their dissemination. However, mechanisms involved in p53-mediated control of cell motility and invasion remain poorly understood. By using the primary ovarian surface epithelium cell culture, we show that conditional inactivation of p53 or expression of its mutant forms results in overexpression of MET receptor tyrosine kinase, a crucial regulator of invasive growth. At the same time, cells acquire increased MET-dependent motility and invasion. Wild-type p53 negatively regulates MET expression by two mechanisms: (i) transactivation of MET-targeting miR-34, and (ii) inhibition of SP1 binding to MET promoter. Both mechanisms are not functional in p53 absence, but mutant p53 proteins retain partial MET promoter suppression. Accordingly, MET overexpression, cell motility, and invasion are particularly high in p53-null cells. These results identify MET as a critical effector of p53 and suggest that inhibition of MET may be an effective antimetastatic approach to treat cancers with p53 mutations. These results also show that the extent of advanced cancer traits, such as invasion, may be determined by alterations in individual components of p53/MET regulatory network.
最近的观察表明,p53 突变不仅负责原发性肿瘤的生长,还负责其扩散。然而,p53 介导的细胞迁移和侵袭控制的机制仍知之甚少。通过使用原发性卵巢表面上皮细胞培养,我们表明条件性失活 p53 或表达其突变形式会导致 MET 受体酪氨酸激酶的过表达,MET 是侵袭性生长的关键调节因子。同时,细胞获得了增强的 MET 依赖性迁移和侵袭能力。野生型 p53 通过两种机制负调控 MET 表达:(i)MET 靶向 miR-34 的转录激活,和(ii)抑制 SP1 与 MET 启动子的结合。这两种机制在 p53 缺失时都不起作用,但突变型 p53 蛋白保留部分 MET 启动子抑制作用。因此,在 p53 缺失的细胞中,MET 过表达、细胞迁移和侵袭特别高。这些结果将 MET 鉴定为 p53 的关键效应因子,并表明抑制 MET 可能是治疗具有 p53 突变的癌症的一种有效的抗转移方法。这些结果还表明,侵袭等晚期癌症特征的程度可能取决于 p53/MET 调节网络中单个成分的改变。